Clinical trials: Irinotecan
Cervix Cancer
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
- Trial name
- NCT00251888
- Testing
- campto (irinotecan), cisplatin (cisplatyl)
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- ARCAGY/ GINECO GROUP
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- MOONRAY-01 (NCT06586515)
- Testing
- LY3962673, Cetuximab, Gemcitabine
- Where
- 52 sites in United States, Canada and 7 more
- Volunteers
- 630 people
- Sponsor
- Eli Lilly and Company
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005068
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Sponsor
- Mayo Clinic
Pancreatic Cancer
MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.
- Trial name
- MASTERPLAN (NCT04089150)
- Testing
- Stereotactic Radiotherapy (SBRT), mFOLFIRINOX, Gemcitabine + Nab-paclitaxel
- Where
- 11 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Pancreatic Cancer
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis, despite the emergence of chemotherapies, unmet medical needs and limited treatment options still exist for patients with metastatic PDAC…
- Trial name
- NCT06378580
- Testing
- Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Luo Cong
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
This phase I/II trial studies the effect of sonoporation in addition to standard of care chemotherapy in treating patients with pancreatic cancer.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Trial name
- NCT04821284
- Testing
- Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil
- Where
- 2 sites in United States, Norway
- Volunteers
- 120 people
- Sponsor
- Flemming Forsberg
Gastrointestinal Cancer, Carcinoma, Neuroendocrine
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
Primary Objective: 1. Assess the clinical activity defined by response rate of irinotecan and cisplatin in untreated patients with metastatic or unresectable high grade neuroendocrine carcinoma of the gastrointestinal tract.
- Trial name
- NCT00353015
- Testing
- Cisplatin, Irinotecan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
The purpose of this study is to assess the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with…
- Trial name
- CR-SEQUENCE (NCT03635021)
- Testing
- FOLFOX regimen, Panitumumab, Bevacizumab
- Where
- Spain
- Volunteers
- 419 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Colorectal Cancer
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or…
- Trial name
- CodeBreaK 301 (NCT06252649)
- Testing
- FOLFIRI Regimen, Sotorasib, Panitumumab
- Where
- 291 sites in United States, Argentina and 33 more
- Volunteers
- 450 people
- Sponsor
- Amgen
Colorectal Cancer, Gastroesophageal Cancer
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer…
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Trial name
- NCT03798626
- Testing
- Gevokizumab, Bevacizumab, Modified FOLFOX6
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 167 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as S-1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00974389
- Testing
- bevacizumab, tegafur-gimeracil-oteracil potassium
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Osaka Medical College
Locally Advanced Pancreatic Cancer
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of Locally Advanced Pancreatic Cancer
- Trial name
- TRIPP-FFX (NCT05466799)
- Testing
- FOLFIRINOX chemotherapy, OncoSil™
- Where
- 14 sites in Australia, Belgium and 3 more
- Volunteers
- 88 people
- Sponsor
- OncoSil Medical Limited
Esophageal Squamous Cell Carcinoma
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2…
- Trial name
- NCT03116152
- Testing
- IBI308, paclitaxel/ irinotecan
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Locally Advanced/Metastatic/Recurrent ESCC
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line…
- Trial name
- NCT07417735
- Testing
- SYS6010, Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)
- Volunteers
- 436 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of CPI-613 when given together with combination chemotherapy in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01835041
- Testing
- 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Pancreas Cancer
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
The study's overall objectives are to evaluate the safety of anakinra in combination with standard chemotherapy regimens in patients with pancreatic ductal adenocarinoma, as well as to collect preliminary immune modulation and…
- Trial name
- NCT02021422
- Testing
- anakinra, Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor Research Institute
Small-cell Lung Cancer
Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (irinotecan plus lobaplatin or irinotecan) for the second-line treatment of recurrent small-cell lung cancer.
- Trial name
- NCT03613753
- Testing
- irinotecan plus lobaplatin, irinotecan
- Where
- China
- Volunteers
- 72 people
- Sponsor
- ShengFa Su
Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC)
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does…
- Conditions
- Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC)
- Trial name
- NCT02312622
- Testing
- Pegylated Irinotecan
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Joel Neal
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002939
- Testing
- irinotecan hydrochloride, paclitaxel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Chicago
Tumors
Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors
The purpose of this study is to assess the safety, establish the maximum tolerated dose (MTD) and generate pharmacokinetic profiles of BSI-201 after IV administration in adult subjects with histologically documented advanced…
- Trial name
- NCT00298675
- Testing
- BSI-201 (iniparib), irinotecan
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanofi